

Non-Hematological Cancers Therapeutic and Drug Pipeline Review H2

Non-Hematological Cancers Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, February 20, 2017

[/EINPresswire.com/](http://EINPresswire.com/) -- Summary

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, [non-hematological cancers](#) are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/464286-global-non-hematological-cancers-market-to-targeted-treatments-and-versatile-biologics> □

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient's tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope

Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from \$73 billion in 2014 to \$141 billion in 2021

- What is the generic penetration?
- Which drugs will achieve blockbuster status?

Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline

- How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action are most common for pipeline drugs?

18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period

- How is their revenue share of the non-hematological cancer market set to change?
- What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
- Visualize the composition of the non-hematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the non-hematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the non-hematological cancer market globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-hematological cancers
- Identify commercial opportunities in the non-hematological cancer deals landscape by analyzing trends in licensing and co-development deals

Table of Content: Key Points

1	Table of Contents	4
1.1	List of Tables	6
1.2	List of Figures	6
2	Introduction	9
2.1	Therapy Area Introduction	9
2.2	Symptoms	10
2.3	Etiology and Pathophysiology	11
2.3.1	Etiology	11
2.3.2	Pathophysiology	12
2.3.3	Tumor Initiation	13
2.3.4	Enhanced Growth, Evasion of Apoptosis and Replicative Immortality	14
2.3.5	Tumor Metabolic Shift	17
2.3.6	Tumor Progression, Invasion and Metastasis	17
2.3.7	Evasion of the Immune Response	19

2.3.8 Cancer Stem Cells	20
2.4 Co-morbidities and Complications	20
2.5 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates	21
2.5.1 Breast Cancer	22
2.5.2 Colorectal Cancer	22
2.5.3 Lung Cancer	23
2.5.4 Prostate Cancer	24
2.6 Treatment	25
2.6.1 Surgery and Radiation Therapy	26
2.6.2 Chemotherapy	27
2.6.3 Hormonal Therapies	29
2.6.4 Targeted Therapies	30
3 Key Marketed Products	32
3.1 Overview	32
3.2 Avastin (bevacizumab)	33
3.3 Herceptin (trastuzumab)	35
3.4 Alimta (pemetrexed)	37
3.5 Zytiga (abiraterone acetate)	38
3.6 Xtandi (enzalutamide)	39
...Continued	

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/464286-global-non-hematological-cancers-market-to-targeted-treatments-and-versatile-biologics> □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/367382864>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.